标题：重组人α-2b干扰素凝胶对尖锐湿疣患者免疫功能及炎症指标的影响

      作者：张怡 1，郭振生 1，杨春 2    1.西安市鄠邑区人民医院皮肤科，陕西 西安 710300；2.陕中中医药大学第二附属医院皮肤科，陕西 咸阳 712000

      卷次： 2019年30卷23期

      【摘要】 目的 分析重组人α-2b干扰素凝胶对尖锐湿疣患者免疫功能及炎症指标的影响。方法 选取2018年1月至2019年1月期间西安市鄠邑区人民医院皮肤科收治的100例尖锐湿疣患者作为研究对象，按随机数表法将患者分为对照组和观察组各50例。对照组患者在常规治疗基础上给予安慰剂治疗，观察组则在常规治疗基础上给予重组人α-2b干扰素凝胶治疗。治疗3个月后，比较两组患者的治疗效果和不良反应，同时比较两组患者治疗前后的白介素-6 (IL-6)、白介素-2 (IL-2)、肿瘤坏死因子-γ (TNF-γ)、干扰素-γ (INF-γ)免疫功能指标和免疫球蛋白A (IgA)、免疫球蛋白G (IgG)、免疫球蛋白M (IgM)血清炎性因子的变化情况。结果 观察组患者的治疗总有效率为96.0%，明显高于对照组的82.0%，差异有统计学意义(P<0.05)；治疗前，两组患者的 INF-γ、IL-6等血清炎性因子水平比较，差异均无统计学意义(P>0.05)；治疗后，观察组和对照组患者 IL-6 [(7.56±1.72) ng/L vs (13.11±3.47) ng/L]、IL-2 [(187.82±28.54) ng/L vs (256.80±36.61) ng/L]、TNF-γ [(4.59±0.89) ng/L vs (7.51±1.87) ng/L]及 INF-γ [(15.69±3.58) ng/L vs(19.97±3.73) ng/L]比较，观察组明显低于对照组，差异均有统计学意义(P<0.05)；治疗前，两组患者的 IgA、IgG及IgM免疫功能指标比较差异均无统计学意义(P>0.05)；治疗后，观察组和对照组患者的 IgM [(1.03±0.22) g/L vs(1.38±0.29) g/L]、IgG [(8.27±2.70) g/L vs (10.37±2.46) g/L]及 IgA [(0.55±0.34) g/L vs (0.77±0.31) g/L]相比，观察组明显低于对照组，差异均有统计学意义(P<0.05)；观察组患者的治疗不良反应率为4.0%，对照组未发现不良反应。结论 重组人α-2b干扰素凝胶治疗尖锐湿疣可明显改善患者的炎症状况，提高患者免疫功能，且安全可靠。
      【关键词】 重组人α-2b干扰素；尖锐湿疣；免疫功能；炎性因子；不良反应；疗效
      【中图分类号】 R752.5+3 【文献标识码】 A 【文章编号】 1003—6350（2019）23—3015—03

Effect of recombinant human interferon α-2b gel on immune function and inflammatory factors in patient withcondyloma acuminatum.
ZHANG Yi 1, GUO Zhen-sheng 1, YANG Chun 2. 1. Department of Dermatology, Huyi DistrictPeople's Hospital of Xi'an, Xi'an 710300, Shaanxi, CHINA; 2. Dermatological Department, the Second Affiliated Hospital ofShaanxi University of Chinese Medicine, Xianyang 712000, Shaanxi, CHINA
【Abstract】 Objective To analyze the effect of recombinant human interferon α-2b (rh IFNα-2b) gel on im-mune function and inflammatory factors in patient with condyloma acuminatum. Methods A total of 100 patients, whoadmitted to Department of Dermatology, Huyi District People's Hospital of Xi'an from January 2018 to January 2019were selected and divided into the observation group and the control group, with 50 patients in each group. The controlgroup was given placebo, while the observation group received rh IFNα-2b gel on the conventional treatment. Therapeu-tic effect and adverse reactions of the two groups were observed. After 3 months of treatment, interleukin-6 (IL-6), inter-leukin-2 (IL-2), tumor necrosis factor (TNF)-α, interferon (IFN)-γ IgA, IgG, IgM of the two groups were analysed.Results The total efficiency of the observation group was 96.0% versus 82.0% of the control group (P<0.05). Beforethe treatment, there was no significant difference in serum inflammatory factors (INF-γ, IL-6) between the groups (P>0.05); After the treatment, IL-6, IL-2, TNF-α, IFN-γ in the observation group were (7.56 ± 1.72) ng/L, (187.82 ±28.54) ng/L, (4.59 ± 0.89) ng/L, (15.69 ± 3.58) ng/L, respectively, which were significantly lower than corresponding(13.11±3.47) ng/L, (256.80±36.61) ng/L, (7.51±1.87) ng/L, (19.97±3.73) ng/L in the control group (all P<0.05). Beforethe treatment, there was no significant difference in IgA, IgG and IgM between the two groups (all P>0.05). After thetreatment, IgM, IgG, Ig A in the observation group were (1.03±0.22) g/L, (8.27±2.70) g/L, (0.55±0.34) g/L, which weresignificantly lower than corresponding (1.38±0.29) g/L, (10.37±2.46) g/L, (0.77±0.31) g/L in the control group (all P<0.05). The total adverse reaction rate of the observation group was 4.0%, and no adverse reactions were found in the con-trol group. Conclusion Recombinant human interferon-alpha-2b gel can significantly improve inflammation and im-mune function of patients with condyloma acuminatum, which is safe and reliable.
      【Key words】 Recombinant human interferon α-2b (rh IFNα-2b) Gel; Condyloma acuminatum; Immune func-tion; Inflammatory factors; Adverse reaction; Curative effect